Advantage Alpha Capital Partners LP Has $500,000 Holdings in Xencor, Inc. (NASDAQ:XNCR)

Advantage Alpha Capital Partners LP decreased its position in Xencor, Inc. (NASDAQ:XNCR) by 42.0% in the third quarter, HoldingsChannel reports. The firm owned 24,861 shares of the biopharmaceutical company’s stock after selling 18,010 shares during the period. Advantage Alpha Capital Partners LP’s holdings in Xencor were worth $500,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Linden Thomas Advisory Services LLC boosted its position in Xencor by 1.6% during the 2nd quarter. Linden Thomas Advisory Services LLC now owns 43,643 shares of the biopharmaceutical company’s stock worth $826,000 after acquiring an additional 699 shares during the period. Baillie Gifford & Co. boosted its holdings in shares of Xencor by 3.3% during the second quarter. Baillie Gifford & Co. now owns 23,530 shares of the biopharmaceutical company’s stock worth $445,000 after purchasing an additional 744 shares during the period. Louisiana State Employees Retirement System grew its position in Xencor by 3.0% during the second quarter. Louisiana State Employees Retirement System now owns 31,000 shares of the biopharmaceutical company’s stock valued at $587,000 after purchasing an additional 900 shares in the last quarter. Diversified Trust Co increased its stake in Xencor by 7.8% in the 2nd quarter. Diversified Trust Co now owns 14,076 shares of the biopharmaceutical company’s stock valued at $266,000 after buying an additional 1,017 shares during the period. Finally, KBC Group NV lifted its position in Xencor by 63.5% in the 3rd quarter. KBC Group NV now owns 3,123 shares of the biopharmaceutical company’s stock worth $63,000 after buying an additional 1,213 shares in the last quarter.

Insider Activity at Xencor

In other news, CEO Bassil I. Dahiyat sold 3,366 shares of the stock in a transaction on Wednesday, November 13th. The stock was sold at an average price of $24.02, for a total transaction of $80,851.32. Following the sale, the chief executive officer now owns 352,615 shares in the company, valued at approximately $8,469,812.30. This represents a 0.95 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, VP John R. Desjarlais sold 68,684 shares of the firm’s stock in a transaction on Monday, November 11th. The shares were sold at an average price of $23.48, for a total value of $1,612,700.32. Following the completion of the sale, the vice president now owns 200,104 shares of the company’s stock, valued at approximately $4,698,441.92. This trade represents a 25.55 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 121,328 shares of company stock valued at $2,879,673 in the last ninety days. Insiders own 5.23% of the company’s stock.

Xencor Trading Down 2.9 %

XNCR stock opened at $25.30 on Wednesday. Xencor, Inc. has a 1-year low of $15.31 and a 1-year high of $26.84. The company has a current ratio of 6.23, a quick ratio of 6.23 and a debt-to-equity ratio of 0.01. The business’s 50 day moving average is $21.57 and its 200-day moving average is $20.39. The firm has a market cap of $1.77 billion, a P/E ratio of -7.91 and a beta of 0.66.

Xencor (NASDAQ:XNCR) last announced its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported ($0.71) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.98) by $0.27. Xencor had a negative return on equity of 30.92% and a negative net margin of 232.77%. The firm had revenue of $10.70 million for the quarter, compared to analysts’ expectations of $14.59 million. During the same period in the prior year, the business posted ($0.40) earnings per share. The business’s revenue was down 81.9% compared to the same quarter last year. Equities analysts anticipate that Xencor, Inc. will post -3.71 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have commented on XNCR. Royal Bank of Canada boosted their target price on Xencor from $31.00 to $34.00 and gave the company an “outperform” rating in a research note on Thursday, September 26th. Wedbush reiterated an “outperform” rating and set a $38.00 price target on shares of Xencor in a report on Thursday, November 7th. BMO Capital Markets restated an “outperform” rating and issued a $34.00 price objective (up previously from $32.00) on shares of Xencor in a report on Friday, November 8th. Finally, JPMorgan Chase & Co. lifted their target price on shares of Xencor from $27.00 to $28.00 and gave the company an “overweight” rating in a research note on Thursday, November 7th. Two investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Xencor currently has a consensus rating of “Moderate Buy” and a consensus target price of $35.75.

About Xencor

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.